Biovie (BIVI) Cash & Equivalents (2013 - 2026)

Biovie has reported Cash & Equivalents for 14 years, with the latest figure at $13.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 43.54% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (down 43.54% YoY) and the FY2025 annual result came in at $17.5 million, down 26.42% from the prior year.
• Cash & Equivalents eased to $13.1 million in Q1 2026 per BIVI's latest filing, from $20.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $45.7 million in Q4 2022 and troughed at $13.1 million in Q1 2026.
• A 5-year average of $23.5 million and a median of $21.2 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 313.19% in 2022, then sank 55.79% in 2023.
• Over 5 years, Cash & Equivalents stood at $45.7 million in 2022, then tumbled by 55.79% to $20.2 million in 2023, then rose by 20.63% to $24.4 million in 2024, then dropped by 15.82% to $20.5 million in 2025, then slumped by 36.23% to $13.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $13.1 million, $20.5 million, and $25.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.